TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
AbstractCancer immunotherapy has produced impressive clinical results in recent years. Despite the success of the checkpoint blockade strategies targeting cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death receptor 1 (PD-1), a large portion of cancer patients have not yet benefited from this novel therapy. T cell immunoglobulin and mucin domain 3 (TIM-3) has been shown to mediate immune tolerance in mouse models of infectious diseases, alloimmunity, autoimmunity, and tumor Immunity. Thus, targeting TIM-3 emerges as a promising approach for further improvement of current immunotherapy. Despite a large amount of experimental data showing an immune suppressive function of TIM-3 in vivo, the exact mechanisms are not well understood. To enable effective targeting of TIM-3 for tumor immunotherapy, further in-depth mechanistic studies are warranted. These studies will also provide much-needed insight for the rational design of novel combination therapy with other checkpoint blockers. In this review, we summarize key evidence supporting an immune regulatory role of TIM-3 and discuss possible mechanisms of action. View Full-Text
Share & Cite This Article
Du, W.; Yang, M.; Turner, A.; Xu, C.; Ferris, R.L.; Huang, J.; Kane, L.P.; Lu, B. TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action. Int. J. Mol. Sci. 2017, 18, 645.
Du W, Yang M, Turner A, Xu C, Ferris RL, Huang J, Kane LP, Lu B. TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action. International Journal of Molecular Sciences. 2017; 18(3):645.Chicago/Turabian Style
Du, Wenwen; Yang, Min; Turner, Abbey; Xu, Chunling; Ferris, Robert L.; Huang, Jianan; Kane, Lawrence P.; Lu, Binfeng. 2017. "TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action." Int. J. Mol. Sci. 18, no. 3: 645.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.